TY - JOUR
T1 - Sotagliflozin, the first dual SGLT inhibitor: Current outlook and perspectives 11 Medical and Health Sciences 1103 Clinical Sciences
AU - Cefalo, Chiara Maria Assunta
AU - Cinti, Francesca
AU - Moffa, Simona
AU - Impronta, Flavia
AU - Mezza, Teresa
AU - Pontecorvi, Alfredo
AU - Giaccari, Andrea
PY - 2019
Y1 - 2019
N2 - Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose. Well-designed clinical trials, have shown that sotagliflozin (as monotherapy or add-on therapy to other anti-hyperglycemic agents) improves glycated hemoglobin in adults with T2D, with beneficial effects on bodyweight and blood pressure. Similar results have been obtained in adults with T1D treated with either continuous subcutaneous insulin infusion or multiple daily insulin injections, even after insulin optimization. A still ongoing phase 3 study is currently evaluating the effect of sotagliflozin on cardiovascular outcomes (ClinicalTrials.gov NCT03315143). In this review we illustrate the advantages and disadvantages of dual SGLT 2/1 inhibition, in order to better characterize and investigate its mechanisms of action and potentialities.
AB - Sotagliflozin is a dual sodium-glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium-glucose co-transporter 2 (determining significant excretion of glucose in the urine, in the same way as other, already available SGLT-2 selective inhibitors) and intestinal SGLT-1, delaying glucose absorption and therefore reducing post prandial glucose. Well-designed clinical trials, have shown that sotagliflozin (as monotherapy or add-on therapy to other anti-hyperglycemic agents) improves glycated hemoglobin in adults with T2D, with beneficial effects on bodyweight and blood pressure. Similar results have been obtained in adults with T1D treated with either continuous subcutaneous insulin infusion or multiple daily insulin injections, even after insulin optimization. A still ongoing phase 3 study is currently evaluating the effect of sotagliflozin on cardiovascular outcomes (ClinicalTrials.gov NCT03315143). In this review we illustrate the advantages and disadvantages of dual SGLT 2/1 inhibition, in order to better characterize and investigate its mechanisms of action and potentialities.
KW - Cardiology and Cardiovascular Medicine
KW - Diabetes
KW - Endocrinology, Diabetes and Metabolism
KW - Hypoglycemic therapy
KW - Internal Medicine
KW - SGLT2 inhibitors
KW - Cardiology and Cardiovascular Medicine
KW - Diabetes
KW - Endocrinology, Diabetes and Metabolism
KW - Hypoglycemic therapy
KW - Internal Medicine
KW - SGLT2 inhibitors
UR - http://hdl.handle.net/10807/132547
UR - http://www.cardiab.com/home/
U2 - 10.1186/s12933-019-0828-y
DO - 10.1186/s12933-019-0828-y
M3 - Article
SN - 1475-2840
VL - 18
SP - 20-N/A
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
ER -